HomeInsightsStock Comparison

Dishman Carbogen Amcis Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Dishman Carbogen Amcis Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jun 24, 2025

Key Highlights

  • The Latest Trading Price of Dishman Carbogen Amcis Ltd is ₹ 247 as of 24 Jun 11:39.
  • The P/E Ratio of Dishman Carbogen Amcis Ltd changed from 5.3 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Remus Pharmaceuticals Ltd changed from 47.2 on March 2024 to 47.2 on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The Market Cap of Dishman Carbogen Amcis Ltd changed from ₹ 840.79 crore on March 2020 to ₹ 3693 crore on March 2024 . This represents a CAGR of 34.45% over 5 yearsThe Market Cap of Remus Pharmaceuticals Ltd changed from ₹ 1016 crore on March 2024 to ₹ 1016 crore on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The revenue of Dishman Carbogen Amcis Ltd for the Mar '25 is ₹ 724.31 crore as compare to the Dec '24 revenue of ₹ 690.01 crore. This represent the growth of 4.97% The revenue of Remus Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Dishman Carbogen Amcis Ltd for the Mar '25 is ₹ 148.91 crore as compare to the Dec '24 ebitda of ₹ 147.8 crore. This represent the growth of 0.75% The ebitda of Remus Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Dishman Carbogen Amcis Ltd changed from ₹ 17 crore to ₹ 43.09 crore over 8 quarters. This represents a CAGR of 59.21% The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Dishman Carbogen Amcis Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 3.5 % on March 2024 . This represents a CAGR of 16.93% over 2 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dishman Carbogen Amcis Ltd

  • Dishman Carbogen Amcis Limited was formerly incorporated as Carbogen Amcis (India) Limited on July 17, 2007.
  • The Company name later on was changed to Dishman Carbogen Amcis Limited effective from 27 March 2017.
  • The Company is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.
  • It has manufacturing and research facilities in India, Switzerland, France, The Netherland and China. During the financial year ended 31 March 2017, Dishman Pharmaceuticals and Chemicals Limited (DPCL) and Dishman Care Limited were merged with DPCL's subsidiary Carbogen Amcis (India) Limited, with the key objective of business consolidation and simplification of the Group structure.

About Remus Pharmaceuticals Ltd

  • Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
  • Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
  • It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
  • The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

Dishman Carbogen Amcis Ltd News Hub

News

Dishman Carbogen Amcis' Ahmedabad facility clears USFDA inspection without observations

The inspection was conducted from 9 June to 13 June 2025. According to the company's state...

Read more

16 Jun 2025 12:15

News

Carbogen Amic AG to co-invest in its manufacturing sites in Switzerland

Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical proce...

Read more

06 Jun 2025 18:05

News

Dishman Carbogen spurts after turnaround Q4 outcome

Consolidated net sales rose 9.41% year-on-year to Rs 716.34 crore in Q4 March 2025. Pre-ta...

Read more

22 May 2025 12:16

News

Dishman Carbogen Amcis to hold board meeting

Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 21 ...

Read more

17 May 2025 14:39

News

Dishman Carbogen Amcis' Shanghai facility clears China regulatory compliance

Dishman Carbogen Amcis announced that its Shanghai facility has successfully obtained its ...

Read more

21 Apr 2025 19:33

News

Dishman Carbogen Amcis receives affirmation in credit ratings

Dishman Carbogen Amcis has received affirmation in credit ratings from India Ratings and R...

Read more

16 Apr 2025 19:56

Remus Pharmaceuticals Ltd News Hub

News

Board of Remus Pharmaceuticals recommends final dividend

Remus Pharmaceuticals announced that the Board of Directors of the Company at its meeting ...

Read more

19 May 2025 09:57

News

Remus Pharmaceuticals to table results

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 17 M...

Read more

13 May 2025 16:52

News

Board of Remus Pharmaceuticals recommends interim dividend

Remus Pharmaceuticals announced that the Board of Directors of the Company at its meeting ...

Read more

09 Nov 2024 16:57

News

Remus Pharmaceuticals to convene board meeting

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 No...

Read more

07 Nov 2024 10:21

News

Remus Pharmaceuticals to convene AGM

Remus Pharmaceuticals announced that the 9th Annual General Meeting (AGM) of the company w...

Read more

31 Aug 2024 15:40

News

Remus Pharmaceuticals to table results

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 16 M...

Read more

10 May 2024 12:07

SWOT Analysis Of Dishman Carbogen Amcis Ltd

Strength

1

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Remus Pharmaceuticals Ltd

Strength

4

S

Weakness

3

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Dishman Carbogen Amcis Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Remus Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dishman Carbogen Amcis Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Dishman Carbogen Amcis Ltd or Remus Pharmaceuticals Ltd?

Market cap of Dishman Carbogen Amcis Ltd is 3,791 Cr while Market cap of Remus Pharmaceuticals Ltd is 1,059 Cr

What are the key factors driving the stock performance of Dishman Carbogen Amcis Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Dishman Carbogen Amcis Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dishman Carbogen Amcis Ltd and Remus Pharmaceuticals Ltd?

As of June 24, 2025, the Dishman Carbogen Amcis Ltd stock price is INR ₹241.85. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹1798.3.

How do dividend payouts of Dishman Carbogen Amcis Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Dishman Carbogen Amcis Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions